Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by TriumphSpitSixon Feb 17, 2021 11:53pm
188 Views
Post# 32592866

RE:Bought deal - placement

RE:Bought deal - placementI don't see this as bad news. For $12, an investor gets 2 shares and 1 warrant, which they will pay $7.50 to exercise for 1 more share. So that's 3 shares at $19.50 total or $6.50/each, just a ~7% difference from where we closed today. AND they're cashed up so in a much stronger negotiating position going forward.

All good as far as I'm concerned.





themagicbox wrote: Did anyone get in on the placement? Closed at 6:30 today. Not a bad deal for the free warrants.

Underwriters will likely keep the price above $6 till the BD closes on the 24th for those that are concened about a plummet. Usually its the penny flippers that care about the day to day.

The big money knows understands the value, and likely got in on the placement. We'll get to see the PH3 with free warrants. Like I said before, look at this month to month and I am sure you'll be very pleased. This will be frustrating for some, but the bigger picture is what matters and we know what we own. 




<< Previous
Bullboard Posts
Next >>